The pooled relative risk was then calculated to compare the seroconversion and adverse reaction rates

The pooled relative risk was then calculated to compare the seroconversion and adverse reaction rates. identified and scored using the Jadad score for inclusion in the meta-analysis. Random effect models were used to calculate the pooled seroconversion rate and adverse reaction rate BIBX 1382 when tests for heterogeneity were significant. The results showed that the pooled seroconversion rate for JEV-I(PHK) (62.23%) was lower than that for JEV-I(Vero) (86.49%) and JEV-L (83.52%), and that the pooled adverse reaction rate for JEV-L (18.09%) was higher than that for JEV-I(PHK) (10.08%) and JEV-I(Vero) (12.49%). The pooled relative risk was then calculated to compare the seroconversion and adverse reaction rates. The results showed that JEV-I(Vero) and JEV-L were more suitable than BIBX 1382 JEV-I(PHK) for inducing fundamental immunity to JE in infants and children less than 2?years of age. = 0.027). Open in a separate window Figure 1. Flow diagram of study selection. Table 1. Characteristics of the 3 Japanese Encephalitis vaccines included in the analysis 0.0001; chi-square = 92.60, df = 4, 0.0001; and chi-squared = 156.15, df = 11, 0.0001, respectively). Therefore, a random effects model27 was used for meta-analysis. The results showed that JEV-I(Vero) had the highest pooled seroconversion rate (86.49%), followed by JEV-L (83.52%), and JEV-I(PHK) (62.23%) (Table 2). Table 2. Pooled analysis of seroconversion rates and adverse reaction rates 0.0001), so a random effects model was used BIBX 1382 to calculate the pooled RR. The result (1.36, 95% CI: 1.21C1.53) showed that the seroconversion rate for JEV-I(Vero) was 1.36?times higher than that for JEV-I(PHK) (Table BIBX 1382 3). Studies conducted by Zhang et?al.,23 Bai et?al.,11 Yang et?al.21 and Guo et?al.18 were used to compare the seroconversion rate between JEV-I(PHK) and JEV-L. In this case, the test for heterogeneity was not significant (chi-squared = 0.28, df = 3, = 0.963); therefore, a fixed effects model was used to calculate the pooled RR. The result (1.38, 95% CI: 1.23C1.56) showed that the seroconversion rate for JEV-L was 1.38?times higher than that for JEV-I(PHK) (Table 3). Studies conducted by Zhang et?al.,24 Li et?al.19 and Guo et?al.18 were used to compare the seroconversion rate between JEV-I(Vero) and JEV-L. The test for heterogeneity was significant (chi-square = 37.34, df = 2, 0.0001), therefore a random effects model was used to calculate the pooled RR. The result (1.00, 95% CI: 0.90C1.12) showed that there was no difference in the seroconversion rate between JEV-I(Vero) and JEV-L (Table 3). Table 3. Comparison of seroconversion and adverse events among JEV-I(Vero), JEV-I(PHK), and Rabbit Polyclonal to ARMX3 JEV-L 0.001Z = 3.40/= 0.001JEV-LeJEV-I(PHK)JEV-LJEV-I(PHK)Pooled343/398222/355100.001.38 (1.23C1.56)39/39455/413100.001.23 (0.71C2.12)Yang, T.L. (2005)21169/191104/16121.431.37 (1.21C1.55)22/20842/17630.000.44 (0.28C0.71)Zhang,H.R.(2002)2363/6947/7328.571.42 (1.18C1.71)12/14110/12340.001.05 BIBX 1382 (0.47C2.34)Guo, S.H. (2002)1820/2917/3521.431.42 (0.93C2.16)5/453/11430.004.22 (1.05C16.94)Bai, Z.Y. (2000)1191/10954/8628.571.33 (1.11C1.60)n.r.n.r.Test of RR = 1Z = 5.30/ 0.001Z = 0.74/= 0.458JEV-LJEV-I(Vero)JEV-LJEV-I(Vero)Pooled218/263197/276100.001.00 (0.90C1.12)62/1,011123/1,288100.000.74 (0.49C1.12)Zhang,Z.H.(2012)24128/14287/14333.331.48 (1.29C1.71)14/14212/14333.331.17 (0.56C2.45)Li, W.J. (2007)1970/9278/10133.330.99 (0.84C1.15)43/82491/1,04033.330.60 (0.42C0.85)Guo, S.H. (2002)1820/2932/3233.330.69 (0.54C0.89)5/4520/10533.330.58 (0.23C1.46)Test of RR = 1Z = 0.08/ 0.196 Open in a separate window aJEV-I, Japanese Encephalitis inactivated vaccine; bVero, Vero cells; cPHK, primary hamster kidney cells; d’ = 0.0167; eJEV-L, Japanese encephalitis live-attenuated vaccine. Safety of the 3 vaccines The pooled adverse reaction rates for the JEV-I(PHK), JEV-I(Vero), and JEV-L vaccines were calculated by extracting the information from 5,18,21-23,25 5,11,18,19,22,24,25 and 617,19-21,23,24 papers, respectively. Tests for heterogeneity were significant (chi-squared = 42.29, df = 4, 0.0001; chi-square = 30.64, df = 4, 0.0001; and chi-squared = 1,407.70, df = 5 0.0001, respectively). Therefore, a random effects model was used to perform meta-analysis. The results showed that JEV-PHK had the lowest pooled adverse reaction rate (10.08%), followed by JEV-I (Vero) (12.49%) and JEV-L (18.09%) (Table 2). Post-hoc multiple comparisons of pooled adverse reaction rates for the 3 vaccines were then conducted. Studies by Guo et?al.,18 Yin et?al.22 and Zhu et?al.25 were used to compare the adverse reaction rate between JEV-I(PHK) and JEV-I(Vero). The test for heterogeneity was significant (chi-square = 20.09, df =.